Literature DB >> 31189776

Prognostic Significance of Phosphorylated Fyn in Patients with Lung Adenocarcinoma after Lung Resection.

Shigeto Nishikawa1, Toshi Menju1, Koji Takahashi1, Ryo Miyata1, Makoto Sonobe1, Akihiko Yoshizawa2, Hiroshi Date1.   

Abstract

PURPOSE: Src family tyrosine kinases, including Fyn, are non-receptor tyrosine kinases that drive malignancy in various kinds of cancers. Fyn has also been suggested to be an effector of epidermal growth factor receptor (EGFR) signaling, and is recognized as a potential therapeutic target. However, little is known about the clinical importance of phosphorylated Fyn (pFyn) in lung adenocarcinoma. The purpose of this study is to examine the prognostic significance of pFyn in this disease.
METHODS: A total of 282 lung adenocarcinoma specimens were collected from patients who underwent surgery at our institute. A tissue microarray was assembled from paraffin-embedded tumor blocks. pFyn expression was analyzed through immunostaining of the tissue microarray and each case was classified as positive or negative. The association of clinical information with pFyn expression was analyzed statistically.
RESULTS: pFyn was positive in 107 cases. A pFyn-positive status was significantly associated with male gender, p53 mutant, pathological stage, tumor size, plural invasion, lymphatic invasion, vascular invasion, and differentiation. pFyn positivity was associated with poor relapse-free survival (RFS; hazard ratio [HR]: 2.11, 95% confidence interval [CI]: 1.32-3.42, p <0.01) and poor overall survival (OS; HR: 1.95, 95% CI: 1.17-3.33, p = 0.01).
CONCLUSION: pFyn expression may affect the prognosis of patients with lung adenocarcinoma after lung resection.

Entities:  

Keywords:  immunohistochemistry; lung adenocarcinoma; phosphorylated Fyn; survival analysis

Mesh:

Substances:

Year:  2019        PMID: 31189776      PMCID: PMC6823168          DOI: 10.5761/atcs.oa.19-00078

Source DB:  PubMed          Journal:  Ann Thorac Cardiovasc Surg        ISSN: 1341-1098            Impact factor:   1.520


  20 in total

1.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

2.  The prognostic role of phospho-Src family kinase analysis in tongue cancer.

Authors:  Ofer Ben-Izhak; Victoria Cohen-Kaplan; Rafael M Nagler
Journal:  J Cancer Res Clin Oncol       Date:  2010-01       Impact factor: 4.553

3.  Fyn is induced by Ras/PI3K/Akt signaling and is required for enhanced invasion/migration.

Authors:  Vipin Yadav; Mitchell F Denning
Journal:  Mol Carcinog       Date:  2010-12-10       Impact factor: 4.784

4.  Fyn mediates transforming growth factor-beta1-induced down-regulation of E-cadherin in human A549 lung cancer cells.

Authors:  An Na Kim; Woo-Kwang Jeon; Kyu-Hyoung Lim; Hui-Young Lee; Woo Jin Kim; Byung-Chul Kim
Journal:  Biochem Biophys Res Commun       Date:  2011-03-01       Impact factor: 3.575

Review 5.  Molecular mechanisms of drug resistance.

Authors:  D B Longley; P G Johnston
Journal:  J Pathol       Date:  2005-01       Impact factor: 7.996

6.  Srcasm inhibits Fyn-induced cutaneous carcinogenesis with modulation of Notch1 and p53.

Authors:  Liang Zhao; Weijie Li; Christine Marshall; Thomas Griffin; Matthew Hanson; Ryan Hick; Tzvete Dentchev; Erik Williams; Adrienne Werth; Christopher Miller; Hasan Bashir; Warren Pear; John T Seykora
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

7.  The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration.

Authors:  Nandini Dey; Hal E Crosswell; Pradip De; Ramon Parsons; Qiong Peng; Jing Dong Su; Donald L Durden
Journal:  Cancer Res       Date:  2008-03-15       Impact factor: 12.701

8.  Tissue microarrays for high-throughput molecular profiling of tumor specimens.

Authors:  J Kononen; L Bubendorf; A Kallioniemi; M Bärlund; P Schraml; S Leighton; J Torhorst; M J Mihatsch; G Sauter; O P Kallioniemi
Journal:  Nat Med       Date:  1998-07       Impact factor: 53.440

9.  Association between epithelial-mesenchymal transition and cancer stemness and their effect on the prognosis of lung adenocarcinoma.

Authors:  Terumasa Sowa; Toshi Menju; Makoto Sonobe; Takao Nakanishi; Kei Shikuma; Naoto Imamura; Hideki Motoyama; Kyoko Hijiya; Akihiro Aoyama; Fengshi Chen; Toshihiko Sato; Masashi Kobayashi; Akihiko Yoshizawa; Hironori Haga; Takashi Sozu; Hiroshi Date
Journal:  Cancer Med       Date:  2015-10-16       Impact factor: 4.452

Review 10.  EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer.

Authors:  Xueli Nan; Chao Xie; Xueyan Yu; Jie Liu
Journal:  Oncotarget       Date:  2017-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.